NCT00326326CompletedPhase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 84
- Locations
- 32
- Primary Endpoint
- HDL-C Safety and Efficacy
Study Overview
Brief Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 30 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
- •Triglycerides between 150-500 mg/dL
- •Fasting Plasma Glucose 140-240 mg/dL
Exclusion Criteria
- •Known cardiovascular, carotid, or peripheral vascular disease
Outcomes
Primary Outcomes
HDL-C Safety and Efficacy
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (32)
Loading locations...
Similar Trials
Terminated
Phase 2
MK0859 Dose-Ranging Study (0859-003)HypercholesterolemiaMixed HyperlipemiaNCT00325455Merck Sharp & Dohme LLC500
Completed
Phase 2
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A StatinHypercholesterolemiaNCT01592240Pfizer354
Active, not recruiting
Phase 2
A Study in Patients With Mixed DyslipidemiaMixed DyslipidemiaNCT06497127Shanghai Argo Biopharmaceutical Co., Ltd.145
Completed
Phase 2
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese SubjectsHypercholesterolemiaNCT02055976Pfizer218
Completed
Phase 3
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442